Editorially independent content, supported with advertising
Is a solution to extending duration with aflibercept (Eylea, Regeneron) in DME patients an 8-mg dose rather than the typical 2-mg dose? Diana Do, MD, joined us to review data from the PHOTON study, which assessed the safety and efficacy of high-dose aflibercept in DME patients. And we hear from Jennifer Lim, MD, who summarized data on extending treatment intervals in the phase 3 YOSEMITE and RHINE studies. Could a significant number of DME patients make it to 12—or even 16—weeks before needing another faricimab (Vabysmo, Genentech/Roche) dose? This Editorially independent content is supported with advertising.
05.17.24
ARVO 2024 Coverage: ≥20-week Dosing in PULSAR and TENAYA/LUCERNEPhilip Storey, MD; and Prof. Sobha Sivaprasad
12.14.23
AAO ’23: Downward Trends in Reimbursement and ChatGPT in the Retina ClinicJohn Thompson, MD and Raymond Iezzi, MD
11.30.23
AAO ’23: Real-World Faricimab Patterns and Improving GA AssessmentsSophie Bakri, MD; and Karl Csaky, MD, PhD
11.22.23
New Retina Radio AAO Late-Breakers: PULSAR at 96 Weeks and Home OCT in Wet AMDJean-François Korobelnik, MD, PhD; and W. Lloyd Clark, MD
11.13.23
New Retina Radio AAO Late-Breakers: ALTITUDE and DIAMONDMark Barakat, MD; and And Hani Salehi-Had, MD
09.01.23
ASRS ’23: Pegcetacoplan Extension Study, and Comparison of Pegcetacoplan and Avacincaptad PegolNathan C. Steinle, MD; and Paul Hahn, MD, PhD
08.11.23
ASRS ’23: Missed Injections for AMD/DME/RVO and Anatomic Response to Vabysmo in Wet AMDChristina Y. Weng, MD, MBA; and Nikolas JS London, MD
05.18.23
New Retina Radio ARVO Coverage: DME Update: 8-mg Aflibercept data and Faricimab TAE in Phase 3Diana Do, MD; and Jennifer Lim, MD
05.11.23
New Retina Radio ARVO Coverage: Faricimab in Wet AMD: Real-world and Phase 3 DataDurga Borkar, MD, MMCi and Varun Chaudhary, MD
12.09.22
AAO '22: Biosimilars’ Practice Implications and Year 2 of YOSEMITE/RHINEGeorge Williams, MD, and Caroline Baumal, MD
Show More